Alantra advises CardioDiagnostics on its sale to CardioOne

Apr 2025

Sell-side advisory

New York – Alantra has acted as the exclusive financial advisor to CardioDiagnostics,  an advanced cardiac monitoring platform, on its sale to CardioOne, a national growth and operational partner supporting independent cardiology practices.

CardioOne’s acquisition of CardioDiagnostics represents a significant step in building a leading virtual care platform within its fully integrated end-to-end practice management technology. This expansion brings together care management, remote patient monitoring, and other integrated solutions, seamlessly embedding them for CardioOne’s existing and future practice partners.

Frederic Laurier, Managing Director at Alantra, said: “Our deep understanding of the market and strong relationships within the cardiac ecosystem enabled us to run a highly efficient process, focusing on a select group of global cardiac device manufacturers and private equity firms with established cardiac platforms. This led to finding the right strategic partner in CardioOne – one that shares CardioDiagnostics’ mission to advance innovation in cardiac care.”

This transaction underscores Alantra’s deep expertise in the healthcare sector, having recently advised in key transactions such as the sales of Halloran Consulting Group to ProductLife Group, Windstar Medical to Merz Lifecare, or vH Essentials® to Wellspring Consumer Healthcare.